Tom 18, Nr 2 (2021)
Komentarz
Opublikowany online: 2021-09-02
Wyświetlenia strony
3072
Wyświetlenia/pobrania artykułu
48
Komentarz do artykułu „Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data”. Lancet 2021; 397: 1085–1094
1
Choroby Serca i Naczyń 2021;18(2):55-59.
Streszczenie
Brak
Referencje
- Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet. 2021; 397(10279): 1085–1094.
- Ibanez B, James S, Angewall S, et al. Wytyczne dotyczące postępowania w ostrym zawale serca z uniesieniem odcinka ST w 2017 roku. Kardiol Pol. 2018; 76: 229–313.
- Sorbets E, Steg PG, Young R, et al. CLARIFY investigators. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019; 40(18): 1399–1407.
- Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998; 97(22): 2202–2212.
- Grajek S. Nowoczesna protekcja w nadciśnieniu tętniczym i przewlekłym zespole wieńcowym. Choroby Serca i Naczyń. 2020; 17(2): 84–95.
- Fox KM, Bertrand ME, Remme WJ, et al. EUROPA Investigators. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am Heart J. 2007; 153(4): 629–635.
- Choi InS, Park IeB, Lee K, et al. Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) investigators. Angiotensin-converting enzyme inhibitors provide better long-term survival benefits to patients with AMI than angiotensin II receptor blockers after survival hospital discharge. J Cardiovasc Pharmacol Ther. 2018 [Epub ahead of print]: 1074248418795897.
- Johannesen C, Mortensen M, Langsted A, et al. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021; 77(11): 1439–1450.
- Ajala ON, Everett BM. Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep. 2020; 22(11): 66.
- Qamar A, Giugliano R, Bohula E, et al. Biomarkers and clinical cardiovascular outcomes with ezetimibe in the IMPROVE-IT trial. J Am Coll Cardiol. 2019; 74(8): 1057–1068.
- Cavus E, Karakas M, Ojeda FM, et al. BiomarCaRE consortium. Association of circulating metabolites with risk of coronary heart disease in a European population: results from the biomarkers for cardiovascular risk assessment in Europe (BiomarCaRE) Consortium. JAMA Cardiol. 2019; 4(12): 1270–1279.
- deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010; 304(22): 2494–2502.
- Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011; 123(13): 1367–1376.
- Ford I, Shah ASV, Zhang R, et al. High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease. J Am Coll Cardiol. 2016; 68(25): 2719–2728.
